Statement on U.S. District Court Decision
on BARACLUDE® (entecavir) Patent
February 12, 2013
Bristol-Myers Squibb is disappointed in the decision of the U.S. District Court for the District of Delaware finding the composition of matter patent for BARACLUDE® (entecavir) invalid, and believes the Court’s decision is incorrect. The Court’s ruling applies only to the company’s patent rights to BARACLUDE in the U.S. The company will appeal the Court’s decision and we are evaluating all other legal options to vigorously defend our intellectual property rights.
BARACLUDE is an innovative medicine developed as part of Bristol-Myers Squibb’s commitment to improving treatment outcomes for patients with viral hepatitis. Bristol-Myers Squibb has a long-term commitment to viral hepatitis and has been at the forefront of the evolving science in this important disease area.
For more information on Bristol-Myers Squibb’s position on intellectual property rights, click here.